Vanguard Group Inc. Boosts Holdings in Viridian Therapeutics, Inc. $VRDN

Vanguard Group Inc. raised its holdings in Viridian Therapeutics, Inc. (NASDAQ:VRDN) by 29.6% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 5,612,144 shares of the company’s stock after purchasing an additional 1,280,161 shares during the quarter. Vanguard Group Inc. owned 0.06% of Viridian Therapeutics worth $174,650,000 at the end of the most recent reporting period.

Several other hedge funds also recently added to or reduced their stakes in the business. Arizona State Retirement System boosted its holdings in Viridian Therapeutics by 8.7% in the fourth quarter. Arizona State Retirement System now owns 18,324 shares of the company’s stock valued at $570,000 after purchasing an additional 1,460 shares during the last quarter. Universal Beteiligungs und Servicegesellschaft mbH purchased a new stake in Viridian Therapeutics in the fourth quarter valued at $1,209,000. PFG Investments LLC acquired a new position in shares of Viridian Therapeutics in the fourth quarter worth about $216,000. J. Safra Sarasin Holding AG raised its position in shares of Viridian Therapeutics by 70.7% in the fourth quarter. J. Safra Sarasin Holding AG now owns 88,271 shares of the company’s stock worth $2,747,000 after acquiring an additional 36,568 shares during the period. Finally, Hennion & Walsh Asset Management Inc. raised its position in shares of Viridian Therapeutics by 9.6% in the fourth quarter. Hennion & Walsh Asset Management Inc. now owns 169,167 shares of the company’s stock worth $5,264,000 after acquiring an additional 14,829 shares during the period.

Viridian Therapeutics Stock Performance

Shares of Viridian Therapeutics stock opened at $16.61 on Monday. Viridian Therapeutics, Inc. has a fifty-two week low of $12.07 and a fifty-two week high of $34.29. The company has a debt-to-equity ratio of 0.10, a quick ratio of 15.15 and a current ratio of 15.15. The firm has a 50-day simple moving average of $21.57 and a two-hundred day simple moving average of $26.94. The company has a market cap of $1.71 billion, a P/E ratio of -5.00 and a beta of 0.82.

Viridian Therapeutics (NASDAQ:VRDN) last released its quarterly earnings results on Tuesday, May 5th. The company reported ($0.90) earnings per share for the quarter, topping the consensus estimate of ($1.06) by $0.16. Viridian Therapeutics had a negative net margin of 490.31% and a negative return on equity of 80.19%. The firm had revenue of $0.14 million during the quarter, compared to the consensus estimate of $0.04 million. During the same quarter in the prior year, the firm earned ($0.87) EPS. The company’s revenue for the quarter was up 95.8% on a year-over-year basis. As a group, equities analysts predict that Viridian Therapeutics, Inc. will post -3.62 earnings per share for the current fiscal year.

More Viridian Therapeutics News

Here are the key news stories impacting Viridian Therapeutics this week:

• Positive Sentiment: HC Wainwright raised its earnings estimates across several future periods, including FY2026, FY2027, FY2028, FY2029 and FY2030, while keeping a Buy rating and a $22 price target, suggesting improving longer-term outlook for Viridian Therapeutics.
• Positive Sentiment: Needham & Company reiterated its Buy rating on Viridian Therapeutics, adding to the recent cluster of bullish analyst support. Viridian Therapeutics’ (VRDN) “Buy” Rating Reiterated at Needham & Company LLC
• Neutral Sentiment: Multiple brokerage updates lifted target prices on VRDN, with one report citing an average target of about $37.07, reflecting continued optimism from analysts. Brokerages Set Viridian Therapeutics, Inc. (NASDAQ:VRDN) Target Price at $37.07
• Negative Sentiment: Viridian Therapeutics completed pricing on an upsized concurrent offering of 1.75% convertible senior notes due 2032 and common stock for $350 million, which can dilute existing shareholders and usually weighs on the stock near term. Viridian Therapeutics Announces Pricing of Upsized Concurrent Public Offerings…
• Negative Sentiment: Market articles also highlighted the financing as a key reason for recent volatility, even as investors look ahead to commercialization of its drug pipeline. Viridian (VRDN) Climbs 33% on Looming Drug Commercialization

Wall Street Analyst Weigh In

VRDN has been the subject of a number of analyst reports. Wedbush decreased their price objective on shares of Viridian Therapeutics from $37.00 to $31.00 and set an “outperform” rating for the company in a research report on Wednesday, April 8th. Evercore reiterated an “outperform” rating and issued a $44.00 price objective on shares of Viridian Therapeutics in a research report on Tuesday, January 20th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Viridian Therapeutics in a research report on Monday, April 20th. Wall Street Zen upgraded shares of Viridian Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Saturday. Finally, Wells Fargo & Company decreased their price objective on shares of Viridian Therapeutics from $29.00 to $20.00 and set an “equal weight” rating for the company in a research report on Tuesday, March 31st. Twelve analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $37.31.

Viridian Therapeutics Company Profile

Viridian Therapeutics, Inc (NASDAQ: VRDN) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted antibody therapeutics for patients suffering from rare and serious diseases. The company’s lead program, VRDN-001, is a fully human monoclonal antibody that antagonizes the insulin-like growth factor-1 receptor (IGF-1R), with an initial focus on thyroid eye disease (TED). By selectively inhibiting IGF-1R signaling, VRDN-001 aims to reduce inflammation and tissue remodeling associated with TED and related disorders.

In addition to VRDN-001, Viridian is advancing a second antibody program, VRDN-002, which targets complement-mediated pathways implicated in autoimmune and inflammatory diseases.